New insights in insurmountable antagonism

@article{Vauquelin2002NewII,
  title={New insights in insurmountable antagonism},
  author={Georges Vauquelin and Isabelle Van Liefde and B B Birzbier and Patrick M. L. Vanderheyden},
  journal={Fundamental \& Clinical Pharmacology},
  year={2002},
  volume={16}
}
Antagonists that produce parallel rightward shifts of agonist dose–response curves with no alteration of the maximal response are traditionally classified as surmountable, while insurmountable antagonists also depress the maximal response. Although the longevity of the antagonist–receptor complex is quoted in many studies to explain insurmountable antagonism, slowly interconverting receptor conformations, allosteric binding sites, and receptor internalization have been evoked as alternative… 
Slow antagonist dissociation and long-lasting in vivo receptor protection.
Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism
TLDR
Simulations are presented to find out whether surmountable antagonism is necessary to allow sufficient D2 receptor stimulation by endogenous dopamine in the striatum during sub-second bursts in dopamine concentration or rather during much slower, activity-related increases thereof.
Label-Free Kinetics: Exploiting Functional Hemi-Equilibrium to Derive Rate Constants for Muscarinic Receptor Antagonists
TLDR
There was an excellent correlation between estimates of antagonist pKB, kon, and koff from functional assays and those determined by competition kinetics using whole-cell N-methylscopolamine binding, validating this approach as a rapid and simple method to functionally profile receptor kinetics of competitive antagonists in the absence of a labeled tracer.
Determination of drug–receptor residence times by radioligand binding and functional assays: experimental strategies and physiological relevance
Drug–receptor interactions were earlier quantified in terms of affinity and efficacy only but residence time has now also been recognized to affect clinical performance. Different approaches to
Carbamazepine derivatives with P2X4 receptor-blocking activity.
Urocontrin, a novel UT receptor ligand with a unique pharmacological profile.
Functional selectivity in GPCR signaling: understanding the full spectrum of receptor conformations.
TLDR
Considerations of receptor heterodimerization add another important dimension to the diversity of cellular responses controlled by GPCRs and will impact the design of improved therapeutics.
Neurokinin 1 Receptor Antagonists: Correlation between in Vitro Receptor Interaction and in Vivo Efficacy
TLDR
Slow functional reversibility is associated with long-lasting in vivo efficacy of NK1R antagonists, whereas the efficacy of compounds with rapid reversability is reflected by their pharmacokinetics.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 102 REFERENCES
Dynamic mechanisms of non-classical antagonism by competitive AT(1) receptor antagonists.
TLDR
It is suggested that a kinetic model might provide a more satisfactory account of the observations of angiotensin-II-mediated responses and provide deeper insights into the pharmacology of G-protein-coupled receptors than the more popular equilibrium models.
Insurmountable AT1 receptor antagonism: message in a model?
The serotonin‐S2 Receptor: A receptor‐transducer coupling model to explain insurmountable antagonist effects
Five serotonin‐S2 antagonists, ketanserin, pipamperone, methysergide, ritanserin, and LSD, were tested for their ability to inhibit signal transduction coupled to the serotonin‐S2 receptor by
Pseudo-noncompetitive antagonism of M1, M3, and M5 muscarinic receptor-mediated Ca2+ mobilization by muscarinic antagonists.
TLDR
Muscarinic receptors M1, M3, and M5 were expressed in Sf9 cells and a direct correlation between the type of inhibition and the measured dissociation rate of the antagonists was observed.
Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism.
TLDR
Evidence is provided for a competitive and rapidly reversible binding interaction of structurally diverse non-peptide antagonists at the AT1 receptor and repeated rinsing of rabbit aorta for up to 5 hr after incubation with 1 microM DuP 753 failed to restore responses to Ang II.
Pseudo-noncompetitive antagonism of muscarinic receptor-mediated cyclic GMP formation and phosphoinositide hydrolysis by pirenzepine.
TLDR
Pirenzepine selectively antagonized muscarinic receptor-mediated cyclic GMP formation in a noncompetitive fashion in mouse neuroblastoma cells (clone N1E-115) and appeared to be noncompetitive and competitive under these two conditions, respectively.
Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action
TLDR
A new model which describes reversible receptor occupancy and occupied receptor‐determined, saturable reduction in the efficacy of AII was proposed, and model‐fitting gave estimates of pKB values for the peptide analogues and agonist affinity and efficacy parameters for AII.
Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors
Abstract— The interaction between the AT1 receptor‐selective antagonist valsartan, and its human receptor, was investigated by direct radioligand binding as well as by its inhibition of angiotensin
...
1
2
3
4
5
...